ORPHA:93346
Spondyloepimetaphyseal dysplasia congenita, Strudwick type
Publications
35,288
Trials
0
Interventional, condition-specific
Researchers
229
Distinct authors in sample
Gene link
COL2A1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare spondyloepimetaphyseal characterized by disproportionate short stature from birth, with shortened limbs and other skeletal abnormalities, including lordosis, kyphoscoliosis, flattened vertebrae, coxa vara, and abnormal epiphyses and metaphyses evident within the first year of life. The presence of metaphyseal differentiates this condition from spondyloepiphyseal congenita (SEDC). Ocular abnormalities, such as myopia, are frequently associated. Characteristic facial features include hypertelorism, a flat facial profile, and the Pierre Robin sequence. An increased risk of cervical (atlantoaxial) instability due to delayed ossification of the odontoid process has also been reported in some patients.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008476
- OMIM:184250
- UMLS:C0700635
Additional Mondo synonyms (1)
spondyloepimetaphyseal dysplasia, Strudwick type
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — COL2A1
- LiteraturePresent
35,288 matched papers (20,142 in last 10 years) Source
- Phenotype characterisedPresent
56 HPO annotations (e.g. Severe short stature; Club-shaped proximal femur; Brachydactyly) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (COL2A1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
56
Associated phenotypes · MONDO:0008476
- Severe short stature
- Club-shaped proximal femur
- Brachydactyly
- Hyperlordosis
- Clinodactyly
Showing 5 of 56 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
35,288
35,288 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
35,288 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
20,142 in the last 10 years · low confidence
Phrase hits: 31 · MeSH hits: 0
Who's working on it?
229
Distinct author names in 31 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bateman JF2 papers · 2022
Musculoskeletal Research, Murdoch Children's Research Institute, Melbourne, Australia.
Papers in Europe PMC - 02Cohn DH2 papers · 2000Papers in Europe PMC
- 03Cormier-Daire V2 papers · 2016
Département de Génétique et INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Fondation Imagine, Hôpital Necker-Enfants malades, AP-HP, Paris, France.
Papers in Europe PMC - 04Eyre DR2 papers · 2000Papers in Europe PMC
- 05Lachman RS2 papers · 2000Papers in Europe PMC
- 06Lamandé SR2 papers · 2022
Musculoskeletal Research, Murdoch Children's Research Institute, Melbourne, Australia.
Papers in Europe PMC - 07Li H2 papers · 2025
BGI-Anhui Clinical Laboratory, BGI-Shenzhen, 236000, Fuyang, China.
Papers in Europe PMC - 08Liu Y2 papers · 2025
Department of Genetics, Jiangxi Maternal and Child Health Hospital, 330006, Nanchang, China.
Papers in Europe PMC - 09Nishimura G2 papers · 2013Papers in Europe PMC
- 10Richards AJ2 papers · 2007
Department of Pathology, University of Cambridge, Cambridge, UK. arichard@hgmp.mrc.ac.uk
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category spondyloepimetaphyseal dysplasia also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: spondyloepimetaphyseal dysplasia
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Spondyloepimetaphyseal dysplasia congenita, Strudwick type — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Spondyloepimetaphyseal dysplasia congenita, Strudwick type" OR "spondyloepimetaphyseal dysplasia, Strudwick type") OR ("COL2A1" OR "COL2A1 syndrome" OR "COL2A1-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Spondyloepimetaphyseal dysplasia congenita, Strudwick type" OR "spondyloepimetaphyseal dysplasia, Strudwick type"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"spondyloepimetaphyseal dysplasia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (35288) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T04:17:31.465Z
